Onco-Innovations Reveals Strategic Developments in Investor Call

On July 2, 2025, Onco-Innovations Limited CEO Thomas O'Shaughnessy updated shareholders on the company's strategic and R&D milestones. The focus was on advancing cancer treatment through innovative therapeutics and AI. The company highlighted progress with its PNKP Inhibitor Technology, marking a shift towards manufacturing and clinical preparation.

The CEO outlined upcoming R&D focus areas, such as selecting research partners and starting GLP preclinical testing. These actions aim to meet 2026 regulatory milestones. In addition, Onco has joined the PROmAI consortium, with AstraZeneca's interest as a testament to its industry relevance.

Further, a new research agreement with the University of Alberta targets glioblastoma multiforme. Onco also uplisted to Cboe Canada to enhance market visibility. The February acquisition of Inka Health AI strengthens Onco's AI capabilities, crucial for precision oncology.

O'Shaughnessy emphasized Onco's merging of novel drug development with AI, focusing on the proprietary Synograph system. The firm aims to advance new therapies for solid tumors via AI.